Japan Tobacco, GlaxoSmithKline Conclude Licensing Agreement for New Drug Candidate.Tokyo, Japan, Apr 20, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Japan Tobacco (JT) has signed a licensing agreement with GlaxoSmithKline (GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) ) for a candidate compound developed by JT. Under the agreement, GSK will receive the worldwide exclusive right to develop and market the compound while JT retains co-promotion rights in Japan. In addition, JT will receive an upfront payment, milestone payments for development and royalties on future sales from GSK. The new compound, which is currently in preclinical trials in Japan, has a property that inhibits the activity of MAPK/ ERK ERK Extracellular Signal-Regulated Kinase ERK Electronic Records Keeping ERK Externally Regulated Kinases kinase (MEK Noun 1. MEK - a terrorist organization formed in the 1960s by children of Iranian merchants; sought to counter the Shah of Iran's pro-western policies of modernization and opposition to communism; following a philosophy that mixes Marxism and Islam it now attacks the ), a kind of enzyme involved in cell proliferation. JT expects the applications of the new compound to include treatment for cancer and inflammation. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion